News

InMed Announces Progress on COPD Treatment Using Cannabinoids

InMed Pharmaceuticals announced that its research and development program using cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD) has made new progress. The company initiated its COPD program in June 2015, leveraging its bioinformatics analysis tool to identify the targets and potential active compounds that could be used…

GOLD Treatment Recommendations Now Include Endobronchial Valves to Manage COPD

Newly updated chronic obstructive pulmonary disease (COPD) management recommendations from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) now include the reduction in bronchoscopic lung volume through the use of endobronchial valves as a treatment option for patients suffering with advanced emphysema and absence of collateral ventilation. The new recommendations are…

GSK Submits FDA New Drug Application for COPD Triple Combination Therapy

GlaxoSmithKline (GSK), together with Innoviva, recently announced GSK submitted a New Drug Application (NDA) with the U.S. FDA for the triple combination therapy FF/UMEC/VI (fluticasone furoate/umeclidinium/vilanterol) to treat chronic obstructive pulmonary disease (COPD). GSK announced earlier this year that it was planning to advance the timing of the filing with…

FDA Grants Marketing Clearance to Propeller Platform for Use with GSK’s Breo Ellipta Inhaler

Propeller Health recently announced that its Propeller platform has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for use with Breo Ellipta, GSK’s dry powder inhaler. On Dec. 1, 2015, Propeller, based in Madison, Wisconsin, and GlaxoSmithKline, headquartered in London, entered into a research and development agreement…

Sunovion Supports U.S. COPD and Epilepsy Awareness Month in November

Marlborough, Mass.-based Sunovion Pharmaceuticals is supporting several advocacy initiatives during the month of November in observance of the coinciding Chronic Obstructive Pulmonary Disease (COPD) and Epilepsy Awareness Months in the U.S., as well as World COPD Day on Nov. 16. Sunovion, a wholly owned subsidiary of Sumitomo Dainippon Pharma…